Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.
相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
33.3%
已完成
2
66.7%
暂无批准数据
- The PRIME trial demonstrated that the PreTRM blood test combined with targeted interventions significantly reduced neonatal morbidity and NICU utilization in over 5,000 low-risk pregnancies. - Screen-guided care resulted in 56% fewer births before 32 weeks, 32% fewer births before 35 weeks, and 20% fewer NICU admissions compared to standard care. - The intervention strategy proved more efficient than current approaches, requiring only 39 women to be screened to prevent one NICU admission versus 150 with standard care. - The study focused on pregnancies not typically identified as high-risk by current screening methods, highlighting the test's value for broader population screening.
- Sera Prognostics, focused on maternal and neonatal health through pregnancy biomarker testing, will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, with CEO Zhenya Lindgardt providing company updates. - The company will report its first quarter fiscal year 2025 financial results on May 7, 2025, followed by a conference call to discuss operational highlights and key developments. - Sera's flagship PreTRM® Test provides individualized risk assessment for spontaneous preterm birth during weeks 18-20 of pregnancy, addressing a significant health concern that affects more than one in ten U.S. infants annually.
